Chemoimmunotherapies as frontline treatment and targeted drugs as second-line treatments.

Ongoing clinical trials are evaluating combination treatment strategies and new drugs. While it is beyond the scope of this discussion to list out all the ongoing clinical trials, we felt it is important to elucidate the concept underlying these trials as below for the readers.



Ibrutinib + Venetoclax

Combination Regimens

yes

Phase III SYMPATICO trial



Obintuzumab + Lenalidomide

Combination Regimens



R-BAC after ibrutinib failure

(Rituximab, Bendamustine, cytarabine) ,

Combination Regimens

MRD: Minimal residual disease; ASO-PCR: allele-specific oligonucleotide PCR; ctDNA: circulating tumor DNA.